Menu Search
Equities

New Ray Medicine International Holding Ltd

6108:HKG.HS

New Ray Medicine International Holding Ltd

Actions
  • Price (HKD)0.042
  • Today's Change-0.003 / -6.67%
  • Shares traded1.43m
  • 1 Year change-10.64%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

New Ray Medicine International Holding Ltd is a company principally engaged in the distribution and trading of pharmaceutical products. The Company operates its businesses through two segments. Distribution and Trading of Pharmaceutical Products segment is mainly engaged in distribution and trading of injection drugs. Provision of Marketing and Promotion Services segment is mainly involved in provision of marketing and promotion services of drugs and chemical reagents. The Company mainly operates its businesses in the domestic market.

  • Revenue in HKD (TTM)35.86m
  • Net income in HKD-12.90m
  • Incorporated2012
  • Employees23.00
  • Location
    New Ray Medicine International Holding LtdRoom 3702-03, Dikai International CenterNo. 19 Dangui RoadHANGZHOU ChinaCHN
  • Websitehttp://www.newraymedicine.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.